Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
2.

Cytoreductive prostatectomy: what is the evidence? A systematic review.

Albisinni S, Aoun F, Diamand R, Al-Hajj Obeid W, Porpiglia F, Roumeguère T, De Nunzio C.

Minerva Urol Nefrol. 2019 Feb;71(1):1-8. doi: 10.23736/S0393-2249.18.03319-2. Epub 2018 Dec 14.

3.

[Surgical treatment of local disease in metastatic prostate cancer.]

Gaya JM, Huguet J, Breda A, Palou J.

Arch Esp Urol. 2018 Mar;71(3):288-297. Review. Spanish.

PMID:
29633950
4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
6.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
7.

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.

Koo KC, Dasgupta P.

Yonsei Med J. 2018 Jul;59(5):567-579. doi: 10.3349/ymj.2018.59.5.567. Review.

8.

Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.

Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A.

Eur Urol. 2015 May;67(5):852-63. doi: 10.1016/j.eururo.2014.09.004. Epub 2014 Sep 17. Review.

PMID:
25240974
9.

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven RV, Peltier A, Gestel DV, Roumeguere T, Otte FX.

World J Urol. 2019 Mar 1. doi: 10.1007/s00345-019-02701-1. [Epub ahead of print]

PMID:
30824985
10.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
11.

Oligometastatic Prostate Cancer.

Navrátil J, Poprach A, Lakomý R, Kocák I, Vašina J, Krupa P, Vyzula R.

Klin Onkol. 2019 Spring;32(2):97-100. doi: 10.14735/amko201997.

PMID:
30995848
12.

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, Delrue L, Billiet I, Duthoy W, Junius S, Huysse W, Lumen N, Ost P.

BMC Cancer. 2014 Sep 15;14:671. doi: 10.1186/1471-2407-14-671.

13.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

14.

Imaging modalities in synchronous oligometastatic prostate cancer.

Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I; EAU-YAU Prostate Cancer Working Party.

World J Urol. 2018 Aug 1. doi: 10.1007/s00345-018-2416-2. [Epub ahead of print]

PMID:
30069582
15.

Role of radical prostatectomy in metastatic prostate cancer: A review.

Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF.

Urol Oncol. 2017 Apr;35(4):125-134. doi: 10.1016/j.urolonc.2017.01.001. Epub 2017 Feb 9. Review.

PMID:
28190749
16.

Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?

Marenco J, Sooriakumaran P.

Arch Esp Urol. 2019 Mar;72(2):174-181.

PMID:
30855019
17.

Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2010;10(27):1-118. Epub 2010 Dec 1.

18.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

19.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P.

World J Urol. 2018 Dec 21. doi: 10.1007/s00345-018-2609-8. [Epub ahead of print]

PMID:
30578441
20.

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.

Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.

PMID:
26356236

Supplemental Content

Support Center